BioSpace News Archive

Landos Biopharma, Inc. today provided a business update and announced financial results for the fourth quarter and full year ended December 31, 2022.

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”) today announced financial results for the fourth quarter and full year ended December 31, 2022, and highlighted recent pipeline and business progress.

Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced financial results for the year ended December 31, 2022, and recent business highlights.

Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full year ended December 31, 2022, and provided a business update.

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced financial results for the full year ended December 31, 2022, and highlighted recent corporate progress.

Eargo, Inc. (Nasdaq: EAR) (“Eargo” or the “Company”), a medical device company on a mission to improve hearing health, today reported its financial results for the fourth quarter ended December 31, 2022.

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today reported financial results for the fourth quarter and year ended December 31, 2022, and provided a corporate update.

Heron Therapeutics, Inc. (Nasdaq: HRTX) today announced financial results for the three and twelve months ended December 31, 2022 and highlighted recent corporate updates.

Biohaven Ltd. (NYSE: BHVN) (“Biohaven” or the “Company”) today reported financial results for the fourth quarter ended December 31, 2022, and provided a review of recent accomplishments and anticipated upcoming milestones.

Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced financial results for the fourth quarter and full year ended December 31, 2022 and other recent business developments.